Genfit SA is a biopharmaceutical company involved in drug discovery and development for the early diagnosis, prevention and treatment of cardiometabolic diseases. The company is headquartered in Loos, Hauts-De-France and currently employs 180 full-time employees. The company went IPO on 2006-12-19. The firm provides therapeutic and diagnostic solutions for rare and serious liver diseases , with a particular interest in diseases with largely unmet medical needs. Its laboratory capabilities include pharmacology, molecular and cellular biology, drug candidate screening, medicinal and analytical chemistry, biochemistry, omics analyses, and data science. Its in-house biobank allows to have unparalleled control and precision in the handling and preservation of biological samples, which is crucial to research. The firm leverage artificial intelligence (image processing tools and language models) to create tools that accelerate daily work and decision-making.
Follow-Up Questions
GNFT hissesinin fiyat performansı nasıl?
GNFT 'in mevcut fiyatı $3.84 'dir, son işlem günde 5.18% decreased etti.
Genfit SA için ana iş temaları veya sektörler nelerdir?
Genfit SA Biotechnology endüstrisine ait ve sektör Health Care 'dir
Genfit SA 'in piyasa değerlemesi nedir?
Genfit SA 'in mevcut piyasa değerlemesi $192.0M 'dir
Genfit SA al, sat, yoksa beklemeli mi?
Wall Street analistlerine göre, 8 analist Genfit SA için analist derecelendirmeleri gerçekleştirdi, bunlar 8 güçlü al, 4 al, 1 tut, 0 sat ve 8 güçlü sat içermektedir
